Literature DB >> 1707934

CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.

M Kahn1, H Sugawara, P McGowan, K Okuno, S Nagoya, K E Hellström, I Hellström, P Greenberg.   

Abstract

p97 is a human tumor-associated Ag present on most melanoma cells that represents a possible target for immunologic attack. To evaluate the capacity of T cells reactive with this protein to promote elimination of melanoma cells expressing p97, a murine model was developed by transfecting a C3H/HeN melanoma with the p97 cDNA, generating p97-specific CD4+ T cells by in vivo immunization of C3H/HeN mice with a vaccinia/p97 recombinant virus followed by in vitro cloning with soluble p97 protein, and determining whether these CD4+ T cells could mediate rejection of pulmonary metastases. Characterization of the T cell clones demonstrated the presence of both I-Ak and I-Ek-restricted clones, although the majority of clones recognized p97 in the context of I-Ek. Analysis of clonal specificity using truncated p97 proteins revealed that at least three epitopes were immunogenic, and further studies with overlapping 15-amino acid peptides from a region of the p97 molecule defined by these truncated proteins identified an immunodominant epitope responsible for the majority of the I-Ek response. The T cell clones were not capable of directly recognizing the p97-expressing melanoma cells but responded to the tumor if syngeneic APC were present to process the tumor-derived p97 Ag. The therapeutic efficacy of these CD4+ T cell clones was evaluated in an adoptive therapy model in which mice bearing metastatic pulmonary lesions were treated by i.v. administration of the p97-specific cells. Despite the inability of the CD4+ clones to directly respond to or lyse the tumor cells, the clones were effective in promoting tumor eradication. In vitro studies demonstrated that this may have reflected secretion of lymphokines that activated macrophages to lyse the tumor. The results suggest that noncytolytic p97-specific CD4+ T cell clones can be effective in therapy of pulmonary melanoma metastases. Moreover, if human T cells reactive with the p97 protein could be generated, the expression of this tumor-associated Ag in melanoma cells might be adequate for such T cells to mediate a therapeutic antitumor response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707934

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.

Authors:  Rachael D Aubert; Alice O Kamphorst; Surojit Sarkar; Vaiva Vezys; Sang-Jun Ha; Daniel L Barber; Lilin Ye; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 3.  CD4 T-cell immunotherapy for chronic viral infections and cancer.

Authors:  Alice O Kamphorst; Rafi Ahmed
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

4.  Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.

Authors:  D R Surman; M E Dudley; W W Overwijk; N P Restifo
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

Review 5.  Vaccines targeting helper T cells for cancer immunotherapy.

Authors:  Marit Melssen; Craig L Slingluff
Journal:  Curr Opin Immunol       Date:  2017-07-26       Impact factor: 7.486

6.  Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.

Authors:  Yilin C Neeley; Kevin T McDonagh; Willem W Overwijk; Nicholas P Restifo; Martin G Sanda
Journal:  Prostate       Date:  2002-11-01       Impact factor: 4.104

7.  The Transitional Endoplasmic Reticulum ATPase p97 Regulates the Alternative Nuclear Factor NF-κB Signaling via Partial Degradation of the NF-κB Subunit p100.

Authors:  Zhao Zhang; Yanyan Wang; Chuanchuan Li; Zhubing Shi; Qian Hao; Wenjia Wang; Xiaomin Song; Yun Zhao; Shi Jiao; Zhaocai Zhou
Journal:  J Biol Chem       Date:  2015-06-25       Impact factor: 5.157

8.  Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.

Authors:  Craig L Slingluff; Gina R Petroni; Kimberly A Chianese-Bullock; Mark E Smolkin; Merrick I Ross; Naomi B Haas; Margaret von Mehren; William W Grosh
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

9.  Luciferase activity as a marker of tumor burden and as an indicator of tumor response to antineoplastic therapy in vivo.

Authors:  L Zhang; K E Hellström; L Chen
Journal:  Clin Exp Metastasis       Date:  1994-03       Impact factor: 5.150

10.  Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

Authors:  Ying Xie; Akgül Akpinarli; Charles Maris; Edward L Hipkiss; Malcolm Lane; Eun-Kyung M Kwon; Pawel Muranski; Nicholas P Restifo; Paul Andrew Antony
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.